Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation

Heart Failure Reviews

Volumn 10, Issue 1, 2005, Pages 31-37

  Joffe, Hylton V ^a   Adler, Gail K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Aldosterone; Cardiovascular diseases; Inflammation; Mineralocorticoid; Receptors; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; AMLODIPINE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; NITRIC OXIDE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; AUTONOMIC DYSFUNCTION; BEHAVIOR MODIFICATION; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; BLOOD VOLUME; CLINICAL TRIAL; ENDOTHELIUM INJURY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY TUBULE ABSORPTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POTASSIUM INTAKE; POTASSIUM TRANSPORT; PRIMARY HYPERALDOSTERONISM; PROTEINURIA; RAT STRAIN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SALT INTAKE; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; SYMPATHETIC TONE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; VASCULITIS;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; OXIDATIVE STRESS; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SODIUM, DIETARY;

EID: 21244458789     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-005-2346-0     Document Type: Review

References (40)

1. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol Metab 1946;6:117-230. 1:CAS:528:DyaH28XhvFGmug%3D%3D
2. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003;88(6):2364-2372. 1:CAS:528:DC%2BD3sXkslCktLk%3D
3. Rocha R, Stier CT, Jr., Kifor I, et al. Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141(10):3871-3878. 1:CAS:528:DC%2BD3cXmvVGmtrk%3D
4. Oestreicher EM, Martinez-Vasquez D, Stone JR, et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 2003;108(20):2517-2523. 1:CAS:528:DC%2BD3sXovVeku7k%3D
5. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002;143(12):4828-4836. 1:CAS:528:DC%2BD38Xpt1eltLs%3D
6. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003;63(5):1791-1800. 1:CAS:528:DC%2BD3sXjslygsb4%3D
7. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283(5):H1802-H1810. 1:CAS:528:DC%2BD38XovVOmt74%3D
8. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: Role of oxidative stress. Am J Pathol 2002;161(5):1773-1781. 1:CAS:528:DC%2BD38XptV2gtLk%3D
9. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269(4 Pt 1):E657-E662. 1:CAS:528:DyaK2MXptVaisLw%3D
10. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993;27(3):341-348. 1:STN:280:ByyB2MfnslY%3D
11. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT, Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31(1 Pt 2):451-458. 1:CAS:528:DyaK1cXptF2lsA%3D%3D
12. Fiebeler A, Schmidt F, Muller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001;37(2 Part 2):787-793. 1:CAS:528:DC%2BD3MXhvVaksrw%3D
13. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002;90(10C):40L-48L. 1:CAS:528:DC%2BD3sXhsVWkur8%3D
14. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002;40(4):504-510. 1:CAS:528:DC%2BD38Xntlams7Y%3D
15. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39(2):351-358. 10.1016/S0735-1097(01)01729-6
16. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105(18):2212-2216. 1:CAS:528:DC%2BD38XktlOku7Y%3D
17. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003;41(6):955-963. 1:CAS:528:DC%2BD3sXksVGju7c%3D
18. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004;109(18):2213-2220. 1:CAS:528:DC%2BD2cXjs1eis74%3D
19. Arima S, Kohagura K, Xu HL, et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 2004;43(2):352-357. 1:CAS:528:DC%2BD2cXitVajsb4%3D
20. Martinez DV, Rocha R, Matsumura M, et al. Cardiac damage prevention by eplerenone: Comparison with low sodium diet or potassium loading. Hypertension 2002;39(2 Pt 2):614-618. 1:CAS:528:DC%2BD38Xhs1WrsbY%3D
21. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-717. 10.1056/NEJM199909023411001
22. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study. Circulation 2003;108(15):1831-1838. 1:CAS:528:DC%2BD3sXnvVajur8%3D
23. White WB, Duprez D, St Hillaire R, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41(5):1021-1026. 1:CAS:528:DC%2BD3sXjtFWqtb8%3D
24. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96(5):2515-2520. 1:CAS:528:DyaK28XltF2nsA%3D%3D
25. Brown NJ, Kim KS, Chen YQ, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000;85(1):336-344. 1:CAS:528:DC%2BD3cXjtl2lsw%3D%3D
26. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342(24):1792-1801. 1:CAS:528:DC%2BD3cXksVequ7Y%3D
27. Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 2000;32(1):73-83. 1:CAS:528:DC%2BD3cXnsVWjsg%3D%3D
28. Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J Hum Hypertens 2002;16(Suppl 2): S2-S6. 1:CAS:528:DC%2BD38XktFWnu78%3D
29. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88(9A):1L-20L. 1:CAS:528:DC%2BD3MXnvFCqsro%3D
30. Nishimura M, Uzu T, Fujii T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999;33(2):261-266. 1:STN:280:DyaK1M7ks1answ%3D%3D
31. Rossi GP, Sacchetto A, Pavan E, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997;95(6):1471-1478. 1:STN:280:ByiB3svgtFM%3D
32. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995;13(12 Pt 2):1801-1802. 1:STN:280:ByiD2MbjtlA%3D
33. Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27(5):1039-1045. 1:STN:280:BymB3cfnslE%3D
34. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-1321. 10.1056/NEJMoa030207
35. Burgess E, Niegowksa J, Tan KW, et al. Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension. Amer J Hypert 2002;15(4 (Part 2)): 23A.
36. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001;345(12):925-926. 1:STN:280:DC%2BD3MrhvVWgtw%3D%3D
37. Epstein M, Buckalew JV, Martinez F, et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Amer J Hypert 2002;15(4 (Part 2)):24A.
38. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41(1):64-68. 1:CAS:528:DC%2BD38Xps1Ohu74%3D
39. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002;103(4):425-431. 1:CAS:528:DC%2BD38XotVWltb8%3D
40. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101(6):594-597. 1:CAS:528:DC%2BD3cXhtlGntL4%3D